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Background

Florida law defines emergency treatment orders (ETOs) as an immediate administration of
psychotropic medications to a person to expeditiously treat symptoms that may present an
immediate danger to the safety of the person or others.1 There is currently little information
on who receives ETOs. In this study, we aim to explore correlations between patients’ demographics and administering ETOs in order to understand this cohort, which could allow for
improved services and alternative interventions.
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Methods

This retrospective study examined data from 1,460 adult patients who were admitted to an
acute inpatient psychiatric unit from January 2015 to December 2017 and who received at
least one ETO during their hospital admission.

Results

Results revealed that younger patients (18–25 years) were at increased risk of receiving more
than one ETO (p=0.039) than patients who were 26 and older. Patients with an elevated body
mass index (BMI) (25 kg/m2 or more) also had a significantly increased likelihood of being
administered more ETOs (≥4 ETOs) than patients with a lower BMI (defined as less than 25
kg/m2 [p=0.037]). Moreover, patients with a length of stay (LOS) of more than 14 days were
more likely to receive more ETOs compared to patients with LOS less than or equal to 14
days (p<0.001). Lastly, patients with a neurocognitive disorder and/or within the schizophrenia spectrum or other psychotic disorders were more likely to receive ETOs (p<0.001) than
patients with other diagnoses.

Conclusion

There are some correlations in administering ETOs in that younger patients with an elevated
BMI, longer LOS and certain diagnoses receive more ETOs. The reason for these findings
is not clear. Therefore, prospective studies should be conducted in order to analyze these
correlations.
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Introduction

Emergency treatment orders (ETOs) are
commonly used in psychiatric hospitals as well
as emergency rooms to calm patients who
are endangering themselves or staff. Current
literature has established the effectiveness
of psychotropic drugs in treating agitation.2-5
However, studies on the demographics of
patients who receive ETOS are still scarce.6 We

conducted a retrospective study to identify any
correlations between patients’ demographics
and administering ETOs, which could improve
patient care and reduce the need for ETOs.

Methods

This retrospective study was approved by the
University of Central Florida Institutional Review Board (IRB ID: SBE-18-13911). The data in
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Table 1. Demographic and Clinical Characteristics by ETO Group for 1,460 Patients
ETO amount (1–3)
ETO amount (≥4)
Variable
Gender

Total

n (%)

1084

n (%)

365
487 (44.9%)

170 (46.6%)

Male

597 (55.1%)

195 (53.4%)

1092

0.002

368

18-25

179 (16.4%)

75 (20.4%)

26-40

438 (40.1%)

108 (29.3%)

41-60

350 (32.1%)

128 (34.8%)

≥61

125 (11.4%)

57 (15.5%)

Race

1092

368

0.161

White

790 (72.3%)

247 (67.1%)

Black

158 (14.5%)

63 (17.1%)

Other/Unknown

144 (13.2%)

58 (15.8%)

BMI

524

162

<18.5

0.022

31 (5.9%)

8 (4.9%)

18.5≤BMI<25

219 (41.8%)

48 (29.6%)

25≤BMI<30

151 (28.8%)

53 (32.7%)

BMI≥30

123 (23.5%)

53 (32.7%)

LOS

1092

<0.001

368

≤14 days

921 (84.3%)

188 (51.1%)

>14 days

171 (15.7%)

180 (48.9%)

Diagnosis

1092

p-value
0.584

Female
Age

368

Schizophrenia Spectrum &
other Psychotic Disorders

444 (40.7%)

213 (57.9%)

<0.001

Bipolar & Related Disorders

364 (33.3%)

122 (33.2%)

0.949

Depressive, Anxiety or
Adjustment Disorders

492 (45.1%)

119 (32.3%)

<0.001

Substance-Related and
Addictive Disorders

230 (21.1%)

48 (13.0%)

0.001

Disruptive, Impulse-Control
and Conduct Disorders

24 (2.2%)

13 (3.5%)

0.159

Personality Disorders

84 (7.7%)

26 (7.1%)

0.693

Neurocognitive Disorders

53 (4.9%)

33 (9.0%)

0.004

this study is from an electronic data warehouse
and was pulled from a cohort of adult patients
who were admitted to one of three psychiatric
units in Florida (North Florida Regional Medical
Center, Osceola Regional Medical Center and
Fort Walton Beach Medical Center Twin Cities
Hospital) over a period of three years. Patients
who had received at least one ETO during their
inpatient psychiatric hospitalization(s) were
362
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selected for analysis. These orders were defined as intramuscular injections of haloperidol,
chlorpromazine, ziprasidone, olanzapine and
lorazepam ordered to calm an agitated patient.
These medications were chosen due to being
the most prevalent psychotropic drugs used
as ETOs in these three psychiatric hospitals.
Patients were classified into two groups based
on the number of ETOs. A low ETO group
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Table 2. Univariate Logistic Regression Analysis for High ETOs (≥4) Based on BMI
BMI
Odds Ratio
95% CI
p-value
BMI <18.5
18.5≤ BMI <25 (Ref.)

1.18

0.51–2.72

0.702

1

25≤ BMI <30

1.60

1.03–2.49

0.037

BMI ≥30

1.97

1.26–3.08

0.003

was defined as one to three ETOs, and a high
ETO group was defined as four or more ETOs.
Patients' final diagnoses at discharge, their demographic factors (age, race, gender and body
mass index [BMI]) and lengths of stay (LOS)
were then compared within the total group and
between the low and high ETO groups.

Statistical Analysis

Univariate analysis was performed to evaluate
potential risk factors of being in the high ETO
group (≥4 ETOs). A multivariate logistic regression model was conducted to determine the
most critical risk factors of a high amount of
ETOs where the model included only the significant factors with a missing value rate of less
than 20% in the univariate analysis. A p-value
of less than 0.05 was considered statistically
significant. All data analyses were conducted
using IBM SPSS Statistics 24.

Results

The study's final analytic file included data
for 1,460 patients who received at least one
ETO. For the total cohort, the mean age was
41.2 years (SD 15.5) with 657 females (45.3%)
and 792 males (54.7%). 71% of patients identified themselves as white while 15.1% identified themselves as black. Other patients'
races (13.83%) were entered in the electronic
medical records as "other" or "unknown". The
prevalence of receiving at least one ETO for
the three hospitals from January 1, 2015 to
December 31, 2017 was 10.07% (1,460/14,493)
with a 95% CI range from 9.59% to 10.58%. The
low ETO group (one to three ETOs) consisted
of 1,092 patients (74.8%) while 368 (25.2%)
patients were in the high ETO group (≥4 ETOs).
The most common diagnosis was schizophrenia
spectrum or other psychotic disorder. Demographics, clinical characteristics, and univariate
analyses by ETO group are presented in Table 1.
The univariate analyses reveals that age
(p=0.002), BMI (p=0.022), LOS (p<0.001) and
a diagnosis of schizophrenia or another psy-

chotic disorder were significantly associated
with a higher administration of ETOs. There
were no significant differences by race. Looking at diagnoses, patients who received more
ETOs (≥4 ETOs) were those diagnosed on the
schizophrenia spectrum, as well as those with
psychotic (p<0.001) or neurocognitive disorders (p=0.004). Patients who received the least
amount of ETOs (one to three ETOs) were
those diagnosed with depression or anxiety
(p<0.001) as well as substance-related and
addictive disorders (p=0.001). There was no difference in the number of ETOs in patients with
personality (p=0.693), disruptive, impulse-control and conduct or bipolar disorders (p=0.949).
However, these categories of diagnoses were
not entirely exclusive to one patient.
Data for BMI as a variable was more limited.
There were a total of 524 of the 1,084 patients
in the low ETO group who had recorded BMI
values and 162 of 365 patients with a BMI recorded in the high ETO group. Table 2 shows
that compared to the patients with a healthy
BMI (18.5≤ BMI <25), patients with a BMI less
than 18.5 kg/m2 did not have an increased risk
of receiving more ETOs (OR=1.18, p=0.702).
Patients with an elevated BMI had an increased
risk of receiving more ETOs (OR=1.60, p=0.037
for patients in the 25≤ BMI <30 group, and
OR=1.97, p=0.003 for patients in the BMI ≥30
group).
The multivariate analysis (Table 3) shows that
compared to patients in the aged 26–40 group,
the younger patients within the 18–25 year
group had an increased risk of receiving more
ETOs (OR=1.47, p=0.039). However, the older patient groups did not have a significantly
increased risk of receiving more ETOs (OR=1.20,
p=0.225 for patients within age 40–60 and
OR=1.19, p=0.419 for patients aged ≥61). Finally,
compared to patients with LOS≤14 days, patients with LOS >14 days had a significantly increased risk of receiving more ETOs (OR=4.68,
p<0.001).
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Table 3. Multivariate Logistic Regression Analysis for High ETO Group (≥4)
Effect
Odds Ratio
95% CI

p-value

Age
18-25

1.47

1.02–2.11

0.039

26-40

1

41-60

1.20

0.88–1.64

0.248

≥61

1.19

0.78–1.80

0.419

4.69

3.57–6.16

<0.001

1.67

1.29–2.16

<0.001

1.23–3.03

0.0043

LOS
≤14 days (Ref.)
>14 days

1

Schizophrenia Spectrum & other Psychotic
Disorders
Yes
No (Ref.)

1

Neurocognitive Disorder
Yes
No (Ref.)

Limitations

This study was limited to Florida. Subsequent
studies should look at the differences in ETO
administration in different states and regions,
as there may be practice and management
differences as well as regulatory differences by state. Another limitation of the study
was missing data. There were undocumented patient weights, which resulted in limited
BMI data. This missing data may be explained
by the level of acuity in inpatient psychiatric
units as patients may not be stable enough to
be weighed during their admission process.
Additionally, we were not able to differentiate
between other races such as Asian or Hispanic
due to the lack of documented races other than
white and black.
Due to the retrospective aspect of the study,
some other data points were not able to be
studied. For instance, the behaviors that were
exhibited when these patients were receiving
ETOs were not documented. We therefore,
do not know the severity of the behaviors or if
any measures were taken to avoid the use of
psychotropic drugs.

Discussion

This study suggests that younger patients
on the schizophrenia spectrum or those who
have other psychotic or neurocognitive disor364

1.93
1

ders with elevated BMI values were more likely
to receive a greater number of ETOs during
their psychiatric admission. The increase in
ETOs may be explained as due to this cohort
of patients being perceived as more threatening than other patients. For example, an older
patient with low BMI may be less threatening
than a younger patient with an elevated BMI.
Furthermore, this study demonstrated that
the administration of ETOs was an indicator
of instability for discharge, which explains the
increase in LOS. These results might be explained as more acute patients have a longer
hospital stay and are less cooperative, thereby
resulting in more ETOs. Future work should be
done prospectively to include reasons for ETOs
and other management alternatives as well as
to obtain more complete BMI, race and ethnicity data. Lastly, it would be important to know
the type of ETOs in order to compare their
side effects and perceived effectiveness.
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